TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30658678

Group type: EXPERIMENTAL
Intervention: Seattle-PAP
Number of subjects: 230

Group type: COMPARATOR
Intervention: FP-CPAP (Fisher & Paykel CPAP)
Number of subjects: 230
Study: 28911260

Group type: EXPERIMENTAL
Intervention: Amiselimod 0.1 mg, 0.2 mg, or 0.4 mg
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Amiselimod (various doses)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 367
Study: 27497361

Group type: EXPERIMENTAL
Intervention: Svelte sirolimus‐eluting coronary stent‐on‐a‐wire Integrated Delivery System (IDS)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stent with durable polymer
Number of subjects: 159
Study: 24478047

Group type: EXPERIMENTAL
Intervention: Taking Care of Sugar DSME program
Number of subjects: 25
Study: 22846379

Group type: EXPERIMENTAL
Intervention: Walking exercise program (6-month home-based)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard medical advice (Control Group)
Number of subjects: 20
Study: 20621419

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Static QST (heat pain thresholds)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic QST (temporal summation)
Number of subjects: 40
Study: 17717914

Group type: EXPERIMENTAL
Intervention: Strengthening Pi and activating blood circulation therapy (SPAB)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Indomethacin and methopterin (Western medicine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of SPAB and Western medicine (CM-WM group)
Number of subjects: 70
Study: 15828855

Group type: EXPERIMENTAL
Intervention: NuvaRing alone for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: NuvaRing for 21 days plus amoxicillin on days 1‐10
Number of subjects: 0

Group type: COMPARATOR
Intervention: NuvaRing for 21 days plus doxycycline
Number of subjects: 0
Study: 12097784

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day reinitiated after relapse from placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day (increased from 20 mg/day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg twice a week (increased from 90 mg weekly)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 11057105

Group type: EXPERIMENTAL
Intervention: Advanced bacteriologically confirmed pulmonary tuberculosis (I group)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Minimal TB changes, usually without clinical signs of the disease, and sputum smear-negative (II group)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 2
Study: 8851780

Group type: EXPERIMENTAL
Intervention: Lifting belt
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Foot motion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no lifting belt)
Number of subjects: 16
Study: 1979763

Group type: EXPERIMENTAL
Intervention: Highly purified pork insulin (Actrapid)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Actrapid Human)
Number of subjects: 8
Study: 34496

Group type: EXPERIMENTAL
Intervention: Triazolam (0.6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study: 31842189

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 185
Study: 31470091

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 99
Study: 26152493

Group type: EXPERIMENTAL
Intervention: Simple task group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Complex task group
Number of subjects: 28
Study: 24434301

Group type: EXPERIMENTAL
Intervention: Low doses of atorvastatin (10 mg daily) or simvastatin (10-20 mg daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Statin-free patients with type 2 diabetes
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 115
Study: 21890323

Group type: EXPERIMENTAL
Intervention: pONS (carbohydrate-containing preconditioning oral nutritional supplement enriched with glutamine, antioxidants, and green tea extract)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: pONS
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 19598302

Group type: EXPERIMENTAL
Intervention: Probiotic combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bl‐04
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17599487

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel discontinued more than 6 days before surgery (group 1, n = 35)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel continued until 3 to 5 days before surgery (group 2, n = 51)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel continued within 2 days of surgery (group 3, n = 20)
Number of subjects: 106
Study: 15141801

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34
Study: 11841525

Group type: EXPERIMENTAL
Intervention: Intervention arm of a trial of the effectiveness of depression treatment
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Patient-centered barriers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Physician-centered barriers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: System barriers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Cluster analysis of barrier scores
Number of subjects: 239
Study: 9823729

Group type: EXPERIMENTAL
Intervention: 0.5% KTP gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.0% KTP gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.0% KTP alternate gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2.0% KTP gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: 25 mg KTP capsule (positive control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All gel formulations
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 42
Study: 7714603

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg tirilazad per day intravenously
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tirilazad per day intravenously
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 6 mg/kg tirilazad per day intravenously
Number of subjects: 245

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 245
Study: 2468745

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2 IV every 3 weeks)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m2 IV every 3 weeks)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 325

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 325
Study: 86292

Group type: EXPERIMENTAL
Intervention: Traditional personalized counseling for 3 months
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Matched instruction (Group IIa)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Mismatched instruction (Group IIb)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Matched instruction (Group IIIa)
Number of subjects: 211

Group type: COMPARATOR
Intervention: High structure in symbolic mode of instruction (Group IIIb)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: High structure in symbolic mode of instruction
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Instructional level of structure
Number of subjects: 211
Study: 30033781

Group type: EXPERIMENTAL
Intervention: Amniotic fluid (AF) Na and K levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amniotic fluid (AF) Na levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amniotic fluid (AF) pH
Number of subjects: 0
Study: 31118101

Group type: EXPERIMENTAL
Intervention: RECO (Remote ischemic conditioning)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No adjunctive intervention (Control)
Number of subjects: 180
Study: 28105513

Group type: EXPERIMENTAL
Intervention: Ginkgo terpene lactones meglumine injection (GMI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26421861

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Prevention (CBP) program
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 316
Study: 23343061

Group type: EXPERIMENTAL
Intervention: Peginesatide administered once monthly
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Epoetin administered one to three times per week
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Peginesatide
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 1608
Study: 16463044

Group type: EXPERIMENTAL
Intervention: Obese women (OB) during submaximal cycling
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of actual VO2 measured with predicted VO2
Number of subjects: 18
Study: 15285777

Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg as Sinemet)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 11
Study: 11103753

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion for 6 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with valsartan pretreatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 9
Study: 8781824

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Strength exercise training
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 1449046

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg x 3) for three months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acipimox (after three months treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acipimox (before treatment)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2936352

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30976922

Group type: EXPERIMENTAL
Intervention: UEScope
Number of subjects: 93

Group type: COMPARATOR
Intervention: Miller
Number of subjects: 93
Study: 29275345

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 320

Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 320
Study: 25935098

Group type: EXPERIMENTAL
Intervention: Polyquaternium-1-preserved travoprost 0.003%
Number of subjects: 864

Group type: COMPARATOR
Intervention: Benzalkonium chloride-preserved travoprost 0.004%
Number of subjects: 864
Study: 23903772

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 30467
Study: 21299297

Group type: EXPERIMENTAL
Intervention: Exercise program (20 or 40 min/day for 13 ± 1.6 weeks)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 171
Study: 19826309

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60-65% 1 repetition maximum (1RM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80-85% 1 repetition maximum (1RM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance exercise at both intensities (60-85% 1RM)
Number of subjects: 13
Study: 16834838

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg once daily
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg once daily
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg once daily
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Tramadol ER 400 mg once daily
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study: 12768357

Group type: EXPERIMENTAL
Intervention: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide after 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo after 4 weeks
Number of subjects: 21
Study: 10671905

Group type: COMPARATOR
Intervention: Milnacipran 12.5 mg, 25 mg, 50 mg, 100 mg (single dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Milnacipran 75 mg (50 mg + 25 mg) per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg (25 mg + 25 mg) per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9176040

Group type: EXPERIMENTAL
Intervention: Urodilatin infusion (20 ng min‐1 kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urodilatin infusion (40 ng min‐1 kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8260563

Group type: EXPERIMENTAL
Intervention: Methylphenidate (optimal drug dosage)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 32
Study: 3910338

Group type: EXPERIMENTAL
Intervention: 0.2% NaF solution rinse every fortnight
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Fluor‐Protector) biannual applications
Number of subjects: 251

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 251
Study: 31327525

Group type: EXPERIMENTAL
Intervention: Statistical shape modelling (SSM)
Number of subjects: 153
Study: 29656744

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 207

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 207
Study: 26842005

Group type: EXPERIMENTAL
Intervention: Kindness questionnaire
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Values essay
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Attributes questionnaire
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 307
Study: 25228778

Group type: EXPERIMENTAL
Intervention: PPL-EMR intervention
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PPL-ASSESS intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Overall improvement
Number of subjects: 132
Study: 22012149

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Weekly Monitoring Control
Number of subjects: 65
Study: 20734060

Group type: EXPERIMENTAL
Intervention: Playing a composition (Robert Schumann's "Phantasiestücke" Op. 73 for clarinet and piano)
Number of subjects: 15
Study: 18593278

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 16097222

Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated Class II children)
Number of subjects: 30
Study: 12523587

Group type: EXPERIMENTAL
Intervention: Triple regimens containing ranitidine bismuth and metronidazole, with either oxytetracycline or spiramycine.
Number of subjects: 183
Study: 10353520

Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil hydrochloride
Number of subjects: 168

Group type: COMPARATOR
Intervention: Halofantrine
Number of subjects: 168
Study: 8602663

Group type: EXPERIMENTAL
Intervention: Carbamazepine group
Number of subjects: 10
Study: 1685166

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise program
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy and exercise therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 61
Study: 7139526

Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Local radiation with or without chemotherapy
Number of subjects: 5
Study: 31440895

Group type: EXPERIMENTAL
Intervention: Patients with Modic changes and considerable inflammation
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients with Modic changes and mild inflammation
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients with extruded discs with Modic changes and considerable inflammation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Patients with bulging discs
Number of subjects: 119
Study: 28944412

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Low-volume polyethylene glycol/ascorbic acid (PEGA)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Split-dose regimen (all solutions)
Number of subjects: 973

Group type: COMPARATOR
Intervention: Single-dose regimen (all solutions)
Number of subjects: 973
Study: 25524612

Group type: EXPERIMENTAL
Intervention: Healthy Text intervention for sun protection (N=187)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Healthy Text intervention for skin self-examination (N=176)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Attention control (N=183)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Skin self-examination intervention (N=176)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Sun protection intervention (N=187)
Number of subjects: 546
Study: 24315548

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: High-pressure balloon angioplasty (HPBA)
Number of subjects: 71
Study: 21111555

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (target INR 2 to 3)
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Fixed-dose ximelagatran 36 mg twice daily
Number of subjects: 7329
Study: 19478213

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622
Study: 17288690

Group type: EXPERIMENTAL
Intervention: Erythropoietic protein therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 0
Study: 15044883

Group type: EXPERIMENTAL
Intervention: Simethicone (80 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No supplemental medication
Number of subjects: 36
Study: 11675170

Group type: EXPERIMENTAL
Intervention: Questionnaire mailed to patients
Number of subjects: 300

Group type: COMPARATOR
Intervention: Questionnaire given at the hospital
Number of subjects: 300

Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Reminders sent after initial response
Number of subjects: 300
Study: 9635472

Group type: EXPERIMENTAL
Intervention: Isokinetic strength of knee extension and flexion at slow speed
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isokinetic strength of knee extension and flexion at fast speed
Number of subjects: 23
Study: 7877874

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to betamethasone and indomethacin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Prenatal exposure to indomethacin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Postnatal GFR measurements on d 10 after birth
Number of subjects: 147
Study: 3243093

Group type: EXPERIMENTAL
Intervention: Cefadroxil once daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cefaclor thrice daily
Number of subjects: 250
Study: 30649899

Group type: EXPERIMENTAL
Intervention: Weighted vest (18.10 kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weighted vest
Number of subjects: 50
Study: 27173517

Group type: EXPERIMENTAL
Intervention: miR-183-5p, miR-486-5p, miR-30c-2-3p, miR-133a-3p (validated using qRT-PCR)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 22 GC specific key miRNAs identified (Fold-change >2, P < 0.05)
Number of subjects: 53
Study: 26314881

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy with passive cycle ergometer intervention (20 min, 20 rpm, once per day, 7 days a week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 28
Study: 24169612

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl added to guideline-recommended treatment including inhibitors of the renin-angiotensin-aldosterone system
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 21159499

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg) after 30 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo after 30 days
Number of subjects: 29
Study: 19051853

Group type: EXPERIMENTAL
Intervention: Direct digital radiographic (DDR) system (RVG‐6000)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional bitewing radiographs (D‐speed film)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both types of radiographs
Number of subjects: 51

Group type: COMPARATOR
Intervention: D‐speed film
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: RVG‐6000 sensor
Number of subjects: 51
Study: 17077374

Group type: EXPERIMENTAL
Intervention: CIMT (n = 106; wearing a restraining mitt on the less‐affected hand while engaging in repetitive task practice and behavioral shaping with the hemiplegic hand)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CIMT (n = 106)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual and customary care (n = 116; ranging from no treatment after concluding formal rehabilitation to pharmacologic or physiotherapeutic interventions)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual and customary care (n = 116)
Number of subjects: 222